» Articles » PMID: 27733065

Photoselective Vaporization of the Prostate: Long-Term Outcomes and Safety During 10 Years of Follow-Up

Overview
Journal J Endourol
Publisher Mary Ann Liebert
Date 2016 Oct 14
PMID 27733065
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the long-term outcomes and safety photoselective vaporization of the prostate (PVP).

Patients And Methods: From April 2005 to December 2015, a total of 1154 patients with benign prostatic hyperplasia underwent PVP. The type of Green Light laser was an 80 W potassium-titanyl-phosphate laser and later a 120 W lithium triborate laser. Before and after surgery, the International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-voiding volume of residual urine (PVR), prostate-specific antigen (PSA) level, and prostate volume were assessed regularly. After surgery, events such as second PVP, transurethral incision, and permanent urethral catheterization were defined as retreatment.

Results: The mean and median periods of follow-up after PVP were 35.4 and 24.0 months, respectively. The maximum duration of follow-up was 125 months. Compared with before surgery, the IPSS, quality of life score, and PSA concentration improved significantly, even at 10 years after PVP; however, Qmax and PVR were not improved at 10 years. The retreatment-free survival rate was 93.9% at 5 years and 79.0% at 10 years. Prostate cancer was found in 27 cases after PVP, and all patients who were found to have prostate cancer remained alive. Prostate cancer-free survival after PVP was 96.7% at 5 years and 89.4% at 10 years.

Conclusion: Our data suggest that the efficacy of PVP was maintained for 10 years; however, it may decrease after more than 10 years. PVP also did not promote the progression of or worsen the prognosis of prostate cancer.

Citing Articles

Comparing GreenLight PVP and HoLEP beyond 5 years: A systematic review of long-term functional outcomes and reoperation rates.

Yim A, Alberto M, Yan X, Bolton D, Wong L, Sethi K BJUI Compass. 2025; 6(2):e483.

PMID: 39963584 PMC: 11832299. DOI: 10.1002/bco2.483.


A case of rapidly progressive prostate cancer with bone and lymph node metastasis after contact laser vaporization for benign prostatic hyperplasia.

Muraoka K, Fujisaki A, Uchida K, Hakamata Y, Kanda Y, Sugiura K IJU Case Rep. 2025; 8(1):47-51.

PMID: 39749293 PMC: 11693099. DOI: 10.1002/iju5.12806.


Incidence of Surgical Reintervention for Benign Prostatic Hyperplasia Following Prostatic Urethral Lift, Transurethral Resection of the Prostate, and Photoselective Vaporization of the Prostate: A TriNetX Analysis.

Feiertag J, Kane J, Clark J Eur Urol Open Sci. 2024; 59:63-70.

PMID: 38298771 PMC: 10829608. DOI: 10.1016/j.euros.2023.11.009.


Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review.

He W, Ding T, Niu Z, Hao C, Li C, Xu Z Front Endocrinol (Lausanne). 2023; 14:1287212.

PMID: 38027158 PMC: 10665564. DOI: 10.3389/fendo.2023.1287212.


The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction.

Roehrborn C, Chin P, Woo H Prostate Cancer Prostatic Dis. 2021; 25(1):79-85.

PMID: 34363010 PMC: 9018420. DOI: 10.1038/s41391-021-00434-0.